<article article-type="article" specific-use="production" xml:lang="en" xmlns:hw="org.highwire.hpp" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:ref="http://schema.highwire.org/Reference" xmlns:hwp="http://schema.highwire.org/Journal" xmlns:l="http://schema.highwire.org/Linking" xmlns:r="http://schema.highwire.org/Revision" xmlns:x="http://www.w3.org/1999/xhtml" xmlns:app="http://www.w3.org/2007/app" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:nlm="http://schema.highwire.org/NLM/Journal" xmlns:a="http://www.w3.org/2005/Atom" xmlns:c="http://schema.highwire.org/Compound" xmlns:hpp="http://schema.highwire.org/Publishing"><front><journal-meta><journal-id journal-id-type="hwp">biorxiv</journal-id><journal-id journal-id-type="publisher-id">BIORXIV</journal-id><journal-title>bioRxiv</journal-title><abbrev-journal-title abbrev-type="publisher">bioRxiv</abbrev-journal-title><publisher><publisher-name>Cold Spring Harbor Laboratory</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.1101/389973</article-id><article-id pub-id-type="other" hwp:sub-type="pisa">biorxiv;389973v1</article-id><article-id pub-id-type="other" hwp:sub-type="pisa-master">biorxiv;389973</article-id><article-id pub-id-type="other" hwp:sub-type="slug">389973</article-id><article-id pub-id-type="other" hwp:sub-type="tag">389973</article-id><article-version>1.1</article-version><article-categories><subj-group subj-group-type="author-type"><subject>Regular Article</subject></subj-group><subj-group subj-group-type="heading"><subject>New Results</subject></subj-group><subj-group subj-group-type="hwp-journal-coll" hwp:journal-coll-id="Epidemiology" hwp:journal="biorxiv"><subject>Epidemiology</subject></subj-group></article-categories><title-group><article-title hwp:id="article-title-1">Medical Nonadherence, Cannabis Use, and Renal Outcome in Systemic Lupus Erythematosis</article-title></title-group><author-notes hwp:id="author-notes-1"><corresp id="cor1" hwp:id="corresp-1">Corresponding Author: Wilmer L. Sibbitt, Jr., MD, MSC 10 5550, 5<sup>th</sup> FL ACC, Department of Internal Medicine, Division of Rheumatology, University of New Mexico Health Sciences Center, Albuquerque, New Mexico, <country>USA</country> 87131, tele 505 272-4761, email: <email hwp:id="email-1">WSibbitt@salud.unm.edu</email></corresp><fn fn-type="conflict" hwp:id="fn-1"><p hwp:id="p-1"><bold>Compliance with Ethical Standards: Disclosure of potential conflicts of interest:</bold> There were no conflicts of interest of any of the authors in this study. This study was funded by US National Institutes of Health research grants (R01 NS035708 and UL1TR001449).</p></fn><fn fn-type="other" hwp:id="fn-2"><p hwp:id="p-2"><bold>Research involving Human Participants and/or Animals:</bold> This research was approved by the institutional review board (IRB) and was in adherence with the Helsinki Declaration and subsequent revisions. Additional IRB approval was obtained prior to analyzing the de-identified database in relation to medical cannabis use.</p></fn><fn fn-type="other" hwp:id="fn-3"><p hwp:id="p-3"><bold>Informed consent:</bold> Each subject provided written informed consent Author Approvals: All authors have seen and approved of the manuscript.</p></fn></author-notes><contrib-group hwp:id="contrib-group-1"><contrib contrib-type="author" hwp:id="contrib-1"><name name-style="western" hwp:sortable="Jalil Basmah A."><surname>Jalil</surname><given-names>Basmah A.</given-names></name><xref ref-type="aff" rid="a1" hwp:id="xref-aff-1-1" hwp:rel-id="aff-1">1</xref></contrib><contrib contrib-type="author" hwp:id="contrib-2"><name name-style="western" hwp:sortable="Qualls Clifford R."><surname>Qualls</surname><given-names>Clifford R.</given-names></name><xref ref-type="aff" rid="a2" hwp:id="xref-aff-2-1" hwp:rel-id="aff-2">2</xref></contrib><contrib contrib-type="author" hwp:id="contrib-3"><name name-style="western" hwp:sortable="Cabacungan Romy J."><surname>Cabacungan</surname><given-names>Romy J.</given-names></name><xref ref-type="aff" rid="a3" hwp:id="xref-aff-3-1" hwp:rel-id="aff-3">3</xref></contrib><contrib contrib-type="author" corresp="yes" hwp:id="contrib-4"><name name-style="western" hwp:sortable="Sibbitt Wilmer L. Jr"><surname>Sibbitt</surname><given-names>Wilmer L.</given-names><suffix>Jr</suffix></name><xref ref-type="aff" rid="a4" hwp:id="xref-aff-4-1" hwp:rel-id="aff-4">4</xref></contrib><contrib contrib-type="author" hwp:id="contrib-5"><name name-style="western" hwp:sortable="Gibb James I."><surname>Gibb</surname><given-names>James I.</given-names></name><xref ref-type="aff" rid="a5" hwp:id="xref-aff-5-1" hwp:rel-id="aff-5">5</xref></contrib><contrib contrib-type="author" hwp:id="contrib-6"><name name-style="western" hwp:sortable="Noronha Leonard E."><surname>Noronha</surname><given-names>Leonard E.</given-names></name><xref ref-type="aff" rid="a6" hwp:id="xref-aff-6-1" hwp:rel-id="aff-6">6</xref></contrib><contrib contrib-type="author" hwp:id="contrib-7"><name name-style="western" hwp:sortable="Fields Roderick A."><surname>Fields</surname><given-names>Roderick A.</given-names></name><xref ref-type="aff" rid="a7" hwp:id="xref-aff-7-1" hwp:rel-id="aff-7">7</xref></contrib><contrib contrib-type="author" hwp:id="contrib-8"><name name-style="western" hwp:sortable="Emil N. Suzanne"><surname>Emil</surname><given-names>N. Suzanne</given-names></name><xref ref-type="aff" rid="a8" hwp:id="xref-aff-8-1" hwp:rel-id="aff-8">8</xref></contrib><contrib contrib-type="author" hwp:id="contrib-9"><name name-style="western" hwp:sortable="Fangtham Monthida"><surname>Fangtham</surname><given-names>Monthida</given-names></name><xref ref-type="aff" rid="a9" hwp:id="xref-aff-9-1" hwp:rel-id="aff-9">9</xref></contrib><contrib contrib-type="author" hwp:id="contrib-10"><name name-style="western" hwp:sortable="Bankhurst Arthur D"><surname>Bankhurst</surname><given-names>Arthur D</given-names></name><xref ref-type="aff" rid="a10" hwp:id="xref-aff-10-1" hwp:rel-id="aff-10">10</xref></contrib><aff id="a1" hwp:id="aff-1" hwp:rev-id="xref-aff-1-1"><label>1</label><institution hwp:id="institution-1">SSM Health Medical Group</institution>. 1035 Bellevue Ave Ste 500, Saint Louis, MO 63117 email: <email hwp:id="email-2">basmahj@yahoo.com</email></aff><aff id="a2" hwp:id="aff-2" hwp:rev-id="xref-aff-2-1"><label>2</label><institution hwp:id="institution-2">Clinical and Translational Research Center, University of New Mexico Health Sciences Center</institution>, Albuquerque, NM, USA 87131. Email: <email hwp:id="email-3">CQualls@salud.unm.edu</email></aff><aff id="a3" hwp:id="aff-3" hwp:rev-id="xref-aff-3-1"><label>3</label><institution hwp:id="institution-3">Arizona Arthritis and Rheumatology Associates</institution>, P.C., 2001 W. Orange Grove Road, Suite 104 Tucson, AZ 85704 <email hwp:id="email-4">romymd23@gmail.com</email></aff><aff id="a4" hwp:id="aff-4" hwp:rev-id="xref-aff-4-1"><label>4</label><institution hwp:id="institution-4">Department of Internal Medicine, Division of Rheumatology and School of Medicine</institution>, MSC 10 5550, 5<sup>th</sup> FL ACC, <institution hwp:id="institution-5">University of New Mexico Health Sciences Center</institution>, Albuquerque, NM, <country>USA</country> 87131. Email: <email hwp:id="email-5">WSibbitt@salud.unm.edu</email></aff><aff id="a5" hwp:id="aff-5" hwp:rev-id="xref-aff-5-1"><label>5</label><institution hwp:id="institution-6">Department of Internal Medicine, Division of Nephrology</institution>, MSC 10 5550, 5<sup>th</sup> FL ACC, <institution hwp:id="institution-7">University of New Mexico Health Sciences Center</institution>, Albuquerque, NM, <country>USA</country> 87131. Email: <email hwp:id="email-6">JGibb@salud.unm.edu</email></aff><aff id="a6" hwp:id="aff-6" hwp:rev-id="xref-aff-6-1"><label>6</label><institution hwp:id="institution-8">Department of Internal Medicine, Division of General Internal Medicine</institution>, MSC 10 5550, 5<sup>th</sup> FL ACC, <institution hwp:id="institution-9">University of New Mexico Health Sciences Center</institution>, Albuquerque, NM, <country>USA</country> 87131. Email: <email hwp:id="email-7">LNoronha@salud.unm.edu</email></aff><aff id="a7" hwp:id="aff-7" hwp:rev-id="xref-aff-7-1"><label>7</label><institution hwp:id="institution-10">Department of Internal Medicine, Division of Rheumatology and School of Medicine</institution>, MSC 10 5550, 5<sup>th</sup> FL ACC, <institution hwp:id="institution-11">University of New Mexico Health Sciences Center</institution>, Albuquerque, NM, <country>USA</country> 87131. Email: <email hwp:id="email-8">RoFields@salud.unm.edu</email></aff><aff id="a8" hwp:id="aff-8" hwp:rev-id="xref-aff-8-1"><label>8</label><institution hwp:id="institution-12">Department of Internal Medicine, Division of Rheumatology and School of Medicine</institution>, MSC 10 5550, 5<sup>th</sup> FL ACC, <institution hwp:id="institution-13">University of New Mexico Health Sciences Center</institution>, Albuquerque, NM, <country>USA</country> 87131. Email: <email hwp:id="email-9">NEmil@salud.unm.edu</email></aff><aff id="a9" hwp:id="aff-9" hwp:rev-id="xref-aff-9-1"><label>9</label><institution hwp:id="institution-14">Department of Internal Medicine, Division of Rheumatology and School of Medicine</institution>, MSC 10 5550, 5<sup>th</sup> FL ACC, <institution hwp:id="institution-15">University of New Mexico Health Sciences Center</institution>, Albuquerque, NM, <country>USA</country> 87131. Email: <email hwp:id="email-10">MFangtham@salud.unm.edu</email></aff><aff id="a10" hwp:id="aff-10" hwp:rev-id="xref-aff-10-1"><label>10</label><institution hwp:id="institution-16">Department of Internal Medicine, Division of Rheumatology and School of Medicine</institution>, MSC 10 5550, 5<sup>th</sup> FL ACC, <institution hwp:id="institution-17">University of New Mexico Health Sciences Center</institution>, Albuquerque, NM, <country>USA</country> 87131. Email: <email hwp:id="email-11">ABankhurst@salud.unm.edu</email></aff></contrib-group><pub-date pub-type="epub-original" hwp:start="2018"><year>2018</year></pub-date><pub-date pub-type="hwp-created" hwp:start="2018-08-15T16:42:11-07:00">
    <day>15</day><month>8</month><year>2018</year>
  </pub-date><pub-date pub-type="hwp-received" hwp:start="2018-08-15T16:42:11-07:00">
    <day>15</day><month>8</month><year>2018</year>
  </pub-date><pub-date pub-type="epub" hwp:start="2018-08-15T16:50:06-07:00">
    <day>15</day><month>8</month><year>2018</year>
  </pub-date><pub-date pub-type="epub-version" hwp:start="2018-08-15T16:50:06-07:00">
    <day>15</day><month>8</month><year>2018</year>
  </pub-date><elocation-id>389973</elocation-id><history hwp:id="history-1">
<date date-type="received" hwp:start="2018-08-10"><day>10</day><month>8</month><year>2018</year></date>
<date date-type="rev-recd" hwp:start="2018-08-10"><day>10</day><month>8</month><year>2018</year></date>
<date date-type="accepted" hwp:start="2018-08-15"><day>15</day><month>8</month><year>2018</year></date>
</history><permissions><copyright-statement hwp:id="copyright-statement-1">© 2018, Posted by Cold Spring Harbor Laboratory</copyright-statement><copyright-year>2018</copyright-year><license license-type="creative-commons" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0/" hwp:id="license-1"><p hwp:id="p-4">This pre-print is available under a Creative Commons License (Attribution-NonCommercial-NoDerivs 4.0 International), CC BY-NC-ND 4.0, as described at <ext-link l:rel="related" l:ref-type="uri" l:ref="http://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0/" hwp:id="ext-link-1">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link></p></license></permissions><self-uri xlink:href="389973.pdf" content-type="pdf" xlink:role="full-text"/><self-uri l:ref="forthcoming:yes" c:role="http://schema.highwire.org/variant/abstract" xlink:role="abstract" content-type="xhtml+xml" hwp:variant="yes"/><self-uri l:ref="forthcoming:yes" c:role="http://schema.highwire.org/variant/full-text" xlink:href="file:/content/biorxiv/vol0/issue2019/pdf/389973v1.pdf" hwp:variant="yes" content-type="pdf" xlink:role="full-text"/><self-uri l:ref="forthcoming:yes" c:role="http://schema.highwire.org/variant/full-text" xlink:role="full-text" content-type="xhtml+xml" hwp:variant="yes"/><self-uri l:ref="forthcoming:yes" c:role="http://schema.highwire.org/variant/source" xlink:role="source" content-type="xml" xlink:show="none" hwp:variant="yes"/><self-uri l:ref="forthcoming:yes" c:role="http://schema.highwire.org/variant/original" xlink:role="original" content-type="xml" xlink:show="none" hwp:variant="yes" xlink:href="389973.xml"/><self-uri content-type="abstract" xlink:href="file:/content/biorxiv/vol0/issue2019/abstracts/389973v1/389973v1.htslp"/><self-uri content-type="fulltext" xlink:href="file:/content/biorxiv/vol0/issue2019/fulltext/389973v1/389973v1.htslp"/><abstract hwp:id="abstract-1"><title hwp:id="title-1">Abstract</title><sec hwp:id="sec-1"><title hwp:id="title-2">Background/Objective</title><p hwp:id="p-5">Non-adherence to recommended medical therapy has been associated with poorer outcomes in systemic lupus erythematosus (SLE). The present research investigated the association of medical non-adherence and cannabis use on renal outcomes of SLE.</p></sec><sec hwp:id="sec-2"><title hwp:id="title-3">Methods</title><p hwp:id="p-6">This was a prospective 5-year longitudinal outcome study of 276 female SLE patients 30.4% who chronically used medical cannabis and 69.5% who did not. Outcomes were determined at 5 years after enrollment in the study.</p></sec><sec hwp:id="sec-3"><title hwp:id="title-4">Results</title><p hwp:id="p-7">Cannabis use in SLE patients was associated with an increased prevalence of neuropsychiatric SLE (p&lt;0.05), opioid analgesic use (p&lt;0.01), cigarette smoking (p&lt;0.001), and non-adherence to the medical regimen (non-cannabis: 3% non-adherence vs. cannabis use: 95% non-adherence, p&lt;0.001). Within the 5-year period, the cannabis group demonstrated a 53% increase in mortality (p=0.12) and 127% increase in end-stage renal disease requiring dialysis (p&lt;0.001). With logistic regression analysis adjusting for SLE disease activity (SLEDAI-2K), cannabis use was an independent predictor of end-stage renal disease: Odds ratio 2.65 (CI 1.32 – 5.32, p&lt;0.01). Adjusting for SLE disease damage (SLICC/ACR-DI), cannabis use remained an independent predictor of end-stage renal disease: Odds ratio 2.0 (CI 1.26 – 6.23, p&lt;0.01). With multivariable analysis adjusting for non-adherence, the effect of cannabis on end-stage renal disease could be largely attributed to an increase in non-adherence to medical therapy.</p></sec><sec hwp:id="sec-4"><title hwp:id="title-5">Conclusions</title><p hwp:id="p-8">Non-adherence to recommended therapy and medical cannabis use are associated with a significant increase in the development of end-stage renal disease in SLE.</p></sec></abstract><kwd-group kwd-group-type="author" hwp:id="kwd-group-1"><title hwp:id="title-6">Key words</title><kwd hwp:id="kwd-1">lupus</kwd><kwd hwp:id="kwd-2">cannabis</kwd><kwd hwp:id="kwd-3">outcome</kwd><kwd hwp:id="kwd-4">marijuana</kwd></kwd-group><counts><page-count count="22"/></counts></article-meta></front><body><sec id="s1" hwp:id="sec-5"><title hwp:id="title-7">Background/Purpose</title><p hwp:id="p-9">Medical cannabis has been used to treat recalcitrant cancer pain, anorexia, and the nausea of chemotherapy [<xref ref-type="bibr" rid="c1" hwp:id="xref-ref-1-1" hwp:rel-id="ref-1">1</xref>]. Cannabis has also been used to treat non-cancer pain, including the pain of sensory neuropathy, multiple sclerosis, fibromyalgia, mixed chronic pain, and rheumatoid arthritis [<xref ref-type="bibr" rid="c1" hwp:id="xref-ref-1-2" hwp:rel-id="ref-1">1</xref>-<xref ref-type="bibr" rid="c3" hwp:id="xref-ref-3-1" hwp:rel-id="ref-3">3</xref>]. Certain medical practitioners incorporate medical cannabis into the therapy of osteoarthritis, rheumatoid arthritis and systemic lupus erythematosus (SLE) with the goal of preventing opioid use, avoiding non-steroidal anti-inflammatory drug toxicity, preserving renal function, and reducing corticosteroid use [<xref ref-type="bibr" rid="c3" hwp:id="xref-ref-3-2" hwp:rel-id="ref-3">3</xref>,<xref ref-type="bibr" rid="c4" hwp:id="xref-ref-4-1" hwp:rel-id="ref-4">4</xref>]. Based on extensive review of the relevant medical literature, Allan and colleagues have recently published guidelines for medical cannabis that recommend that medical cannabis be restricted to resistant medical conditions for which there is some evidence of beneficial effect (neuropathic pain, palliative and end-of-life pain, chemotherapy-induced nausea and vomiting, and spasticity due to multiple sclerosis or spinal cord injury) (1,2). Although there has been important research into the effects of medical cannabis in many other conditions characterized by chronic pain, the literature for cannabis-based management in SLE is especially lacking [<xref ref-type="bibr" rid="c1" hwp:id="xref-ref-1-3" hwp:rel-id="ref-1">1</xref>-<xref ref-type="bibr" rid="c4" hwp:id="xref-ref-4-2" hwp:rel-id="ref-4">4</xref>].</p><p hwp:id="p-10">In the present study, we examined the 5-year outcomes of SLE patients who regularly used medical cannabis versus those who did not use cannabis. The present research, to our knowledge, is one of the first epidemiologic investigations into associations of medical cannabis use with SLE disease outcomes, including end-stage renal disease.</p></sec><sec id="s2" hwp:id="sec-6"><title hwp:id="title-8">Methods</title><p hwp:id="p-11">This research was approved by the institutional review board (IRB) and was in adherence with the Helsinki Declaration and subsequent revisions. The study design was a cross-sectional and longitudinal observational study of outcome. 276 SLE female patients were studied over a period of 5 years and were enrolled consecutively as encountered in clinic. Each subject provided written informed consent. Inclusion criteria included any patient with SLE, age 18-80. Exclusion criteria were age &lt; 18 years, age &gt; 80 years, male gender, pre-existing end-stage renal disease, renal transplantation, and any patient with an autoimmune diagnosis other than SLE (overlap disease). The population sample included diverse social, racial, and ethnic backgrounds with North American Hispanics (58%) and Caucasian Whites (34%) being the dominant participants.</p><p hwp:id="p-12">The diagnosis of SLE was established in each subject using the American College of Rheumatology (ACR) revised criteria for the classification for SLE [<xref ref-type="bibr" rid="c5" hwp:id="xref-ref-5-1" hwp:rel-id="ref-5">5</xref>]. SLE disease activity was determined with the System Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) and SLE disease injury was measured with the Systemic Lupus Erythematosus Collaborating Clinics/American College of Rheumatology Damage Index (SLICC/ACR-DI) [<xref ref-type="bibr" rid="c6" hwp:id="xref-ref-6-1" hwp:rel-id="ref-6">6</xref>,<xref ref-type="bibr" rid="c7" hwp:id="xref-ref-7-1" hwp:rel-id="ref-7">7</xref>]. Each of these metrics was further subcategorized into Neuro-SLEDAI-2K consisting of the neurologic components of SLEDAI-2K, and Neuro-SLICC/ACR-DI consisting of the neurologic components of SLICC/ACR-DI. Neuropsychiatric SLE (NPSLE) was characterized by the ACR nomenclature and case definitions for NPSLE [<xref ref-type="bibr" rid="c8" hwp:id="xref-ref-8-1" hwp:rel-id="ref-8">8</xref>]. After collection this prospective 5-year database was then de-identified. Additional IRB approval was obtained prior to analyzing the de-identified database in relation to medical cannabis use. Outcomes were determined at 5 years after enrollment in the study.</p><p hwp:id="p-13">Medical cannabis in this study was defined as smoked cannabis (marijuana) and was categorically defined as at least 2 smoked cannabis units (cigarettes or pipes) per week and the subject was categorized as “cannabis” or “non-cannabis” with 84 patients (30.4%) regularly using cannabis and 192 (69.5%) with no cannabis use. New Mexico is one of the states in the USA with locally legal medical cannabis programs. Medical cannabis was not prescribed or provided by the rheumatologist, rather by the patient’s primary care provider, medical cannabis specialist, or pain specialist. Demographics and outcomes recorded were age of SLE onset (years), age (years), SLE disease duration (years), tobacco use (years), tobacco use (pack per day), tobacco use ever, opiate use, weight (kilograms), pain, morning stiffness (hours), SLICC/ACRDI, Neuro-SLICC/ACRDI, Non-Neuro-SLICC/ACRDI, SLEDAI-2K, Neuro-SLEDAI-2K, Non-Neuro-SLEDAI-2K, antinuclear antibody (ANA) titer, anti-DNA antibody (IU), anti-phospholipid antibodies (IgG, IgM, IgA in GPL, MPL, APL units, respectively), rheumatoid factor (IU), antiribosmal P (IU), family history (arthritis, SLE, rheumatoid arthritis), active renal disease (glomerulonephritis), renal failure/end-stage renal disease, night pain, death, and Sjogren’s syndrome. Pain was accessed with the 10 cm visual analogue pain scale (VAS). Opioid dosage (the study population predominately used oxycodone 5-10 mg tablets) was normalized to 7.5 mg morphine milligram equivalent (MME) (equivalent to 5 mg oxycodone), and was reported as the number of 7.5 mg MME tablets per month [<xref ref-type="bibr" rid="c9" hwp:id="xref-ref-9-1" hwp:rel-id="ref-9">9</xref>]. Non-adherence (non-adherence) was defined by admission by the patient that they were not taking their SLE medications, blood testing for mycophenolate levels, and/or by missing more than 20% of their clinic appointments (“a no-show”); cancellations with rescheduling and hospitalizations were not counted as “no-show” or non-adherence. Survival and death of SLE subjects were determined by following up with each patient or, if the patient could not be contacted, the patient’s family, autopsy reports from the medical examiner, chart review, and searching the Social Security</p><p hwp:id="p-14">Death Index for death/benefit files relating to the study participant [<xref ref-type="bibr" rid="c10" hwp:id="xref-ref-10-1" hwp:rel-id="ref-10">10</xref>]. This combined methodology permitted 100% follow-up of all subjects at 5 years. Renal failure/end-stage renal disease was defined in a patient who 1) required long-term hemo-or peritoneal dialysis, or 2) required and underwent renal transplantation.</p><sec id="s2a" hwp:id="sec-7"><title hwp:id="title-9">Statistical Methods</title><p hwp:id="p-15">The major comparison was between cannabis and non-cannabis users. Statistical differences between measurement data were determined with Student t-test and categorical data with Fisher’s exact method, associations were determined initially with univariable regression analysis and afterward multivariable models were created to determine independent effects on dependent variables.</p></sec></sec><sec id="s3" hwp:id="sec-8"><title hwp:id="title-10">Results</title><p hwp:id="p-16">Demographics and results of the 276 subjects with SLE are shown in <xref rid="tbl1" ref-type="table" hwp:id="xref-table-wrap-1-1" hwp:rel-id="T1">Tables 1</xref> and <xref rid="tbl2" ref-type="table" hwp:id="xref-table-wrap-2-1" hwp:rel-id="T2">2</xref>. No significant differences were observed in SLE disease duration, SLE disease activity (SLEDAI-2K), injury/damage from SLE (SLICC/ACR-DI), ANA titer, dsDNA antibody, anti-phospholipid antibodies (IgG, IgM, IgA), rheumatoid factor, active renal disease, night pain, morning stiffness, pain by VAS, Sjogren’s syndrome, anti-Smith antibody, RNP antibody, and anti-ribosomal P antibody in the cannabis and non-cannabis SLE groups.</p><table-wrap id="tbl1" orientation="portrait" position="float" hwp:id="T1" hwp:rev-id="xref-table-wrap-1-1 xref-table-wrap-1-2 xref-table-wrap-1-3 xref-table-wrap-1-4 xref-table-wrap-1-5 xref-table-wrap-1-6"><object-id pub-id-type="other" hwp:sub-type="pisa">biorxiv;389973v1/TBL1</object-id><object-id pub-id-type="other" hwp:sub-type="slug">T1</object-id><object-id pub-id-type="publisher-id">tbl1</object-id><label>TABLE 1.</label><caption hwp:id="caption-1"><p hwp:id="p-17">Comparison of SLE Patients with no Cannabis Use versus Cannabis Use.</p></caption><graphic xlink:href="389973_tbl1" position="float" orientation="portrait" hwp:id="graphic-1"/></table-wrap><table-wrap id="tbl2" orientation="portrait" position="float" hwp:id="T2" hwp:rev-id="xref-table-wrap-2-1 xref-table-wrap-2-2 xref-table-wrap-2-3 xref-table-wrap-2-4 xref-table-wrap-2-5 xref-table-wrap-2-6 xref-table-wrap-2-7"><object-id pub-id-type="other" hwp:sub-type="pisa">biorxiv;389973v1/TBL2</object-id><object-id pub-id-type="other" hwp:sub-type="slug">T2</object-id><object-id pub-id-type="publisher-id">tbl2</object-id><label>TABLE 2.</label><caption hwp:id="caption-2"><p hwp:id="p-18">Comparison of SLE Patients with and without Cannabis Use</p></caption><graphic xlink:href="389973_tbl2" position="float" orientation="portrait" hwp:id="graphic-2"/></table-wrap><p hwp:id="p-19">However, the cannabis smokers had a younger age (p&lt;0.001), a younger age of SLE onset (p&lt;0.001), a more common family history of SLE (p=0.03), a greater percentage of opioid analgesic use (p=0.01), more consumption per month of 7.5 mg MME tablets of opioid analgesics (p=0.008), increased tobacco use (p&lt;0.001), increased active neuropsychiatric SLE symptoms (Neuro-SLEDAI-2K) (p=0.04), more neurologic injury (Neuro-SLICC/ACR-DI) (p=0.02), increased non-adherence with medical therapy (non-cannabis non-adherence: 3% vs. cannabis use: 95% non-adherence, p value &lt; 0.001), and over a 5 year period a 127% increase in end-stage renal disease (non-cannabis: 11% vs. cannabis: 25%, p=0.006).</p><p hwp:id="p-20">The percentage of deaths over a 5 year period increased in the cannabis group by 53% (non-cannabis: 15.6% deaths/5 years; cannabis: 23.8% deaths/5 years,) although this did not reach statistical significance (p=0.12)</p><p hwp:id="p-21">Logistic regression analysis adjusting for disease activity (SLEDAI-2K) cannabis use was an independent predictor of end-stage renal disease: Odds ratio 2.65 (CI 1.32 – 5.32, p= 0.006).</p><p hwp:id="p-22">Adjusting for disease injury (SLICC/ACR-DI) cannabis use remained an independent predictor of end-stage renal disease: Odds ratio 2.0 (CI 1.26 – 6.23, p= 0.01).</p><p hwp:id="p-23">With multivariable analysis adjusting for non-adherence cannabis use was not an independent predictor of end-stage renal disease: Odds ratio 0.9 (CI 0.7 – 1.1, p= 0.92). Similarly, with multivariable analysis adjusting for cannabis use non-adherence was also not an independent predictor of end-stage renal disease: Odds ratio 1.0 (CI 0.8 – 1.2, p= 0.94). Thus, with multivariable analysis adjusting for both cannabis use and non-adherence, the effect of cannabis use on the increase in end-stage renal disease could be statistically explained by an increase in non-adherence to the recommended medical regimen. Thus, cannabis use and non-adherence were statistically dependent on each other and were essentially equal predictors of developing end-stage renal disease over a 5 year period.</p></sec><sec id="s4" hwp:id="sec-9"><title hwp:id="title-11">Discussion</title><p hwp:id="p-24">The present study demonstrates that medical cannabis use in SLE is not associated with lower VAS pain scores, lower SLE disease activity or injury, preserved renal function, or other beneficial findings, but rather is associated with increased neuropsychiatric SLE, opioid analgesic use, cigarette smoking, and non-adherence with the recommended medical regimen with a 53% increase in the death rate and a 127% increase in end-stage renal disease within the 5 year period (<xref rid="tbl1" ref-type="table" hwp:id="xref-table-wrap-1-2" hwp:rel-id="T1">Tables 1</xref> and <xref rid="tbl2" ref-type="table" hwp:id="xref-table-wrap-2-2" hwp:rel-id="T2">2</xref>). SLE is often characterized by chronic pain related to arthritis, neuropathy, Raynaud’s phenomenon, low back pain, vertebral compression fractures, headache, fibromyalgia, and aseptic necrosis of the hips [<xref ref-type="bibr" rid="c11" hwp:id="xref-ref-11-1" hwp:rel-id="ref-11">11</xref>]. Although many SLE patients can cope with their pain, a substantial proportion (up to 42%) do not cope well and show signs of pain-related dysfunction, including distress, activity interference, catastrophising, and interpersonal difficulties [<xref ref-type="bibr" rid="c12" hwp:id="xref-ref-12-1" hwp:rel-id="ref-12">12</xref>]. Treating pain in these individuals is difficult due to concomitant coagulation and renal disorders often excluding the use of non-steroidal anti-inflammatory drugs, thus, there has been a recent interest in treating chronic pain in SLE with medical cannabis to avoid the potential toxic effects of non-steroidal anti-inflammatory drugs, opiates, and excessive corticosteroids [<xref ref-type="bibr" rid="c4" hwp:id="xref-ref-4-3" hwp:rel-id="ref-4">4</xref>].</p><p hwp:id="p-25">Cannabinoids are a group of compounds present in the Cannabis plant (Cannabis sativa L.) and mediate their physiological and behavioral effects by activating specific cannabinoid receptors [<xref ref-type="bibr" rid="c1" hwp:id="xref-ref-1-4" hwp:rel-id="ref-1">1</xref>-<xref ref-type="bibr" rid="c3" hwp:id="xref-ref-3-3" hwp:rel-id="ref-3">3</xref>]. With the discovery of the cannabinoid receptors (CB1 and CB2) and the endocannabinoid system, research in this field has expanded exponentially. Cannabinoids have been shown to act as potent immunosuppressive and anti-inflammatory agents in vitro and have been reported to mediate potential beneficial effects in a wide range of immune-mediated diseases such as multiple sclerosis, diabetes, peripheral neuropathy, septic shock, rheumatoid arthritis, and allergic asthma [<xref ref-type="bibr" rid="c1" hwp:id="xref-ref-1-5" hwp:rel-id="ref-1">1</xref>-<xref ref-type="bibr" rid="c3" hwp:id="xref-ref-3-4" hwp:rel-id="ref-3">3</xref>]. Thus, since cannabinoids can be immunosuppressive and there are cannabinoid receptors in symptomatic tissues, it might be expected that cannabis use might reduce the activity of SLE and improve SLE outcomes.</p><p hwp:id="p-26">The prototypical use of smoked medical cannabis is in cancer therapy to reduce anxiety, reduce nausea, improve appetite, and reduce pain, where cannabis is not expected to substantially alter the outcome of the disease [<xref ref-type="bibr" rid="c1" hwp:id="xref-ref-1-6" hwp:rel-id="ref-1">1</xref>,<xref ref-type="bibr" rid="c2" hwp:id="xref-ref-2-1" hwp:rel-id="ref-2">2</xref>]. In other chronic diseases with less increased mortality than cancer, such as chronic low back pain, osteoarthritis, myofascial-fibromyalgia, and impingement neuropathy, the positive or negative effects of cannabis outcome would require extremely large cohorts with many years of observation to determine significant differences in mortality and morbidity since these diseases themselves have only long-term effects on mortality [<xref ref-type="bibr" rid="c1" hwp:id="xref-ref-1-7" hwp:rel-id="ref-1">1</xref>,<xref ref-type="bibr" rid="c2" hwp:id="xref-ref-2-2" hwp:rel-id="ref-2">2</xref>,<xref ref-type="bibr" rid="c13" hwp:id="xref-ref-13-1" hwp:rel-id="ref-13">13</xref>]. However, without effective medical therapy SLE has a much accelerated morbidity and mortality than many of these other chronic diseases, thus the beneficial or deleterious effects of medical cannabis on outcome if present could potentially be observed in a much shorter time frame [<xref ref-type="bibr" rid="c14" hwp:id="xref-ref-14-1" hwp:rel-id="ref-14">14</xref>].</p><p hwp:id="p-27">Similar to the results of the present study in SLE patients, the use of cannabis in other diseases has been associated with an increased rate of non-adherence to medications and recommended medical therapy [<xref ref-type="bibr" rid="c15" hwp:id="xref-ref-15-1" hwp:rel-id="ref-15">15</xref>-<xref ref-type="bibr" rid="c17" hwp:id="xref-ref-17-1" hwp:rel-id="ref-17">17</xref>]. In human immunodeficiency virus (HIV) patients cannabis use has been associated with a nearly 100% increase in non-adherence to antiretroviral therapy [<xref ref-type="bibr" rid="c15" hwp:id="xref-ref-15-2" hwp:rel-id="ref-15">15</xref>]. Cannabis use has also been associated with non-adherence to insulin regimens in diabetes mellitus resulting in increased hospitalizations for ketoacidosis and infections [<xref ref-type="bibr" rid="c16" hwp:id="xref-ref-16-1" hwp:rel-id="ref-16">16</xref>]. Cannabis use is also associated with non-adherence to medications in depression and other psychiatric conditions [<xref ref-type="bibr" rid="c17" hwp:id="xref-ref-17-2" hwp:rel-id="ref-17">17</xref>]. In the present study in SLE patients, medical cannabis use was associated with an increase to 93% non-adherence to the recommended medical regimen (<xref rid="tbl2" ref-type="table" hwp:id="xref-table-wrap-2-3" hwp:rel-id="T2">Table 2</xref>), further supporting the close association of cannabis and non-adherence reported in other conditions [<xref ref-type="bibr" rid="c15" hwp:id="xref-ref-15-3" hwp:rel-id="ref-15">15</xref>-<xref ref-type="bibr" rid="c17" hwp:id="xref-ref-17-3" hwp:rel-id="ref-17">17</xref>]. This increase in non-adherence to the medical regimen with cannabis use in SLE is of even greater concern since the baseline non-adherence to medical therapy in SLE is reported also to be very high, ranging from 43% to 83% [<xref ref-type="bibr" rid="c18" hwp:id="xref-ref-18-1" hwp:rel-id="ref-18">18</xref>,<xref ref-type="bibr" rid="c19" hwp:id="xref-ref-19-1" hwp:rel-id="ref-19">19</xref>].</p><p hwp:id="p-28">Using Medicaid data Feldman and colleagues have reported that SLE patients are up to 79-83% non-adherent with medication and that this non-adherence is associated with greater use of emergency services and increased hospitalizations [<xref ref-type="bibr" rid="c20" hwp:id="xref-ref-20-1" hwp:rel-id="ref-20">20</xref>]. Uribe, Segovia, and colleagues have demonstrated that non-adherence in SLE was associated with a younger age, single marital status, ‘no shows’ to clinics, greater disease activity and more severe SLE manifestations (serositis, renal involvement, positive anti-ds-DNA antibodies) that are associated with poorer outcomes [<xref ref-type="bibr" rid="c21" hwp:id="xref-ref-21-1" hwp:rel-id="ref-21">21</xref>]. Rivera et al reported that non-adherence to medications in SLE patients is associated with increased flares of lupus, including active lupus glomerulonephritis [<xref ref-type="bibr" rid="c22" hwp:id="xref-ref-22-1" hwp:rel-id="ref-22">22</xref>]. Renal transplantation often utilizes similar immunosuppressive drug regimens that are used to treat lupus nephritis, and non-adherence to immunosuppressive therapy has been increasingly recognized as a major contributing cause to episodes of rejection and graft loss [<xref ref-type="bibr" rid="c23" hwp:id="xref-ref-23-1" hwp:rel-id="ref-23">23</xref>,<xref ref-type="bibr" rid="c24" hwp:id="xref-ref-24-1" hwp:rel-id="ref-24">24</xref>]. Thus, since cannabis use has been associated with non-adherence to therapy, and non-adherence to therapy has been associated with more severe SLE manifestations and active lupus glomerulonephritis, it is not surprising that cannabis use is also associated with increased non-adherence and an associated increased prevalence of end-stage renal disease in SLE as shown in the present study (<xref rid="tbl2" ref-type="table" hwp:id="xref-table-wrap-2-4" hwp:rel-id="T2">Table 2</xref>) [<xref ref-type="bibr" rid="c15" hwp:id="xref-ref-15-4" hwp:rel-id="ref-15">15</xref>-<xref ref-type="bibr" rid="c24" hwp:id="xref-ref-24-2" hwp:rel-id="ref-24">24</xref>].</p><p hwp:id="p-29">It is possible that cannabis use contributes to non-adherence to medical regimens in SLE by the well-known deleterious effects of cannabinoids on motivation, memory, and other cognitive functions [<xref ref-type="bibr" rid="c13" hwp:id="xref-ref-13-2" hwp:rel-id="ref-13">13</xref>-<xref ref-type="bibr" rid="c17" hwp:id="xref-ref-17-4" hwp:rel-id="ref-17">17</xref>,<xref ref-type="bibr" rid="c25" hwp:id="xref-ref-25-1" hwp:rel-id="ref-25">25</xref>]. Cannabis use has previously been associated with increased neurocognitive defects in autoimmune diseases, a finding that the present study confirms with increased prevalence of neuropsychiatric SLE (increased Neuro-SLEDAI-2K and increased Neuro-SLICC/ACR-DI) (<xref rid="tbl1" ref-type="table" hwp:id="xref-table-wrap-1-3" hwp:rel-id="T1">Table 1</xref>) [<xref ref-type="bibr" rid="c25" hwp:id="xref-ref-25-2" hwp:rel-id="ref-25">25</xref>]. Further, cannabis use in musculoskeletal diseases and arthritis has been associated with the increased use of narcotic analgesics, which the present study confirms in SLE (<xref rid="tbl1" ref-type="table" hwp:id="xref-table-wrap-1-4" hwp:rel-id="T1">Tables 1</xref> and <xref rid="tbl2" ref-type="table" hwp:id="xref-table-wrap-2-5" hwp:rel-id="T2">2</xref>) [<xref ref-type="bibr" rid="c26" hwp:id="xref-ref-26-1" hwp:rel-id="ref-26">26</xref>]. The present study demonstrated no beneficial changes in immune parameters, SLE disease activity (SLEDAI-2K), or SLE disease damage (SLICC/ACRDI) in medical cannabis users, but increases in neuropsychiatric SLE (Neuro-SLEDAI-2K and Neuro-SLICC/ACRDI) and increased end-stage renal disease suggesting that the immunomodulatory effects of medical cannabis in SLE are either minor or are overwhelmed by the marked increase in non-adherence to recommended medical therapy (<xref rid="tbl1" ref-type="table" hwp:id="xref-table-wrap-1-5" hwp:rel-id="T1">Tables 1</xref> and <xref rid="tbl2" ref-type="table" hwp:id="xref-table-wrap-2-6" hwp:rel-id="T2">2</xref>).</p><p hwp:id="p-30">Patients with SLE have a high risk for glomerulonephritis that without effective medical intervention often results in renal failure and the need for dialysis and renal transplantation [<xref ref-type="bibr" rid="c14" hwp:id="xref-ref-14-2" hwp:rel-id="ref-14">14</xref>,<xref ref-type="bibr" rid="c27" hwp:id="xref-ref-27-1" hwp:rel-id="ref-27">27</xref>,<xref ref-type="bibr" rid="c28" hwp:id="xref-ref-28-1" hwp:rel-id="ref-28">28</xref>]. Cannabis use has been reported to cause membranous glomerulopathy, another reason for caution in SLE patients with preexisting renal disease [<xref ref-type="bibr" rid="c29" hwp:id="xref-ref-29-1" hwp:rel-id="ref-29">29</xref>]. In contrast, Greenan and colleagues have reported that recreational cannabis use was not associated with worse outcomes after renal transplantation; however, most of these patients were not SLE patients [<xref ref-type="bibr" rid="c30" hwp:id="xref-ref-30-1" hwp:rel-id="ref-30">30</xref>]. To date there are few published trials regarding renal transplant survival specifically in SLE patients who do and do not utilize medical cannabis, and the present study does not provide further information on this group.</p><p hwp:id="p-31">The present study demonstrates that end-stage renal disease increases by 127% in SLE patients who are medical cannabis users, and that the statistical cannabis effect can be explained by an increase in non-adherence with the medical regimen. Medical cannabis use is also associated with increased neuropsychiatric symptoms in SLE patients, and it is also possible that deterioration in cognition and motivation exacerbated by cannabis may be contributing to increased non-adherence to therapy, a factor that may be important in that a majority of SLE patient already have baseline neurocognitive defects [<xref ref-type="bibr" rid="c8" hwp:id="xref-ref-8-2" hwp:rel-id="ref-8">8</xref>,<xref ref-type="bibr" rid="c25" hwp:id="xref-ref-25-3" hwp:rel-id="ref-25">25</xref>]. Presently, guidelines for the use of medical cannabis in SLE have not been formulated largely because there is little objective data on which to base these recommendations. However, based on the present study and a review of the published medical literature, SLE is presently not one of the conditions where medical cannabis can be administered with expectations of a predictable benefit [<xref ref-type="bibr" rid="c1" hwp:id="xref-ref-1-8" hwp:rel-id="ref-1">1</xref>,<xref ref-type="bibr" rid="c2" hwp:id="xref-ref-2-3" hwp:rel-id="ref-2">2</xref>].</p><p hwp:id="p-32">There are a number of limitations to this study. The association of cannabis and non-adherence with poorer outcomes may reflect greater disease activity, severity, and individual predisposition rather than be directly causative. Medical cannabis use could predispose to the observed non-adherence to therapy, but an alternative is that the addictive personality type who uses medical cannabis is the same personality type who is non-adherent to therapy with or without cannabis. This latter possibility is supported by the increase in concomitant substance use (tobacco and opioid analgesics) in the medical cannabis users (<xref rid="tbl1" ref-type="table" hwp:id="xref-table-wrap-1-6" hwp:rel-id="T1">Tables 1</xref> and <xref rid="tbl2" ref-type="table" hwp:id="xref-table-wrap-2-7" hwp:rel-id="T2">2</xref>). Secondly, this study was restricted only to women with SLE, not men, as men with SLE generally have a poorer outcome and different drug use patterns than women with SLE. However, most SLE patients are women, so this study is generally applicable to the majority of SLE patients. The present study was a cross-sectional, prospective cohort study that accurately reflected our SLE population over 5 years, but was not an incipient cohort study with subjects enrolled on diagnosis and was not a randomized controlled trial, thus, the reported associations may not be causative. The period of observation was 5 years, longer or shorter periods of observation may have different results. Since the potency and regimens for use of medical cannabis have not been standardized, the dosing and the potency of the medical cannabis were intrinsically variable, thus, certain SLE patients could have had extremely potent or weak cannabis that could have influenced the results. Finally, only smoked medical cannabis was studied, not capsules, tablets, topical preparations, extracts, synthetic cannabinoids, or purified cannabinoids that are increasingly available.</p></sec><sec id="s5" hwp:id="sec-10"><title hwp:id="title-12">Conclusion</title><p hwp:id="p-33">This 5-year outcome study indicates that medical cannabis use in SLE is not associated with reduced pain, less use of opioid analgesics or diminished SLE disease activity. Rather, medical cannabis use in SLE is associated with an increased incidence of neuropsychiatric SLE, accentuated opioid use, increased non-adherence to recommended therapy, and an increased progression to end-stage renal disease.</p></sec></body><back><ref-list hwp:id="ref-list-1"><title hwp:id="title-13">REFERENCES</title><ref id="c1" hwp:id="ref-1" hwp:rev-id="xref-ref-1-1 xref-ref-1-2 xref-ref-1-3 xref-ref-1-4 xref-ref-1-5 xref-ref-1-6 xref-ref-1-7 xref-ref-1-8"><label>1.</label><citation publication-type="journal" citation-type="journal" ref:id="389973v1.1" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-1"><string-name name-style="western" hwp:sortable="Allan GM"><surname>Allan</surname> <given-names>GM</given-names></string-name>, <string-name name-style="western" hwp:sortable="Ramji J"><surname>Ramji</surname> <given-names>J</given-names></string-name>, <string-name name-style="western" hwp:sortable="Perry D"><surname>Perry</surname> <given-names>D</given-names></string-name>, <string-name name-style="western" hwp:sortable="Ton J"><surname>Ton</surname> <given-names>J</given-names></string-name>, <string-name name-style="western" hwp:sortable="Beahm NP"><surname>Beahm</surname> <given-names>NP</given-names></string-name>, <string-name name-style="western" hwp:sortable="Crisp N"><surname>Crisp</surname> <given-names>N</given-names></string-name>, <string-name name-style="western" hwp:sortable="Dockrill B"><surname>Dockrill</surname> <given-names>B</given-names></string-name>, <string-name name-style="western" hwp:sortable="Dubin RE"><surname>Dubin</surname> <given-names>RE</given-names></string-name>, <string-name name-style="western" hwp:sortable="Findlay T"><surname>Findlay</surname> <given-names>T</given-names></string-name>, <string-name name-style="western" hwp:sortable="Kirkwood J"><surname>Kirkwood</surname> <given-names>J</given-names></string-name>, <string-name name-style="western" hwp:sortable="Fleming M"><surname>Fleming</surname> <given-names>M</given-names></string-name>, <string-name name-style="western" hwp:sortable="Makus K"><surname>Makus</surname> <given-names>K</given-names></string-name>, <string-name name-style="western" hwp:sortable="Zhu X"><surname>Zhu</surname> <given-names>X</given-names></string-name>, <string-name name-style="western" hwp:sortable="Korownyk C"><surname>Korownyk</surname> <given-names>C</given-names></string-name>, <string-name name-style="western" hwp:sortable="Kolber MR"><surname>Kolber</surname> <given-names>MR</given-names></string-name>, <string-name name-style="western" hwp:sortable="McCormack J"><surname>McCormack</surname> <given-names>J</given-names></string-name>, <string-name name-style="western" hwp:sortable="Nickel S"><surname>Nickel</surname> <given-names>S</given-names></string-name>, <string-name name-style="western" hwp:sortable="Noël G"><surname>Noël</surname> <given-names>G</given-names></string-name>, <string-name name-style="western" hwp:sortable="Lindblad AJ."><surname>Lindblad</surname> <given-names>AJ.</given-names></string-name> <article-title hwp:id="article-title-2">Simplified guideline for prescribing medical cannabinoids in primary care</article-title>. <source hwp:id="source-1">Can Fam Physician.</source> <year>2018</year> Feb;<volume>64</volume>(<issue>2</issue>):<fpage>111</fpage>–<lpage>120</lpage>.</citation></ref><ref id="c2" hwp:id="ref-2" hwp:rev-id="xref-ref-2-1 xref-ref-2-2 xref-ref-2-3"><label>2.</label><citation publication-type="journal" citation-type="journal" ref:id="389973v1.2" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-2"><string-name name-style="western" hwp:sortable="Allan GM"><surname>Allan</surname> <given-names>GM</given-names></string-name>, <string-name name-style="western" hwp:sortable="Finley CR"><surname>Finley</surname> <given-names>CR</given-names></string-name>, <string-name name-style="western" hwp:sortable="Ton J"><surname>Ton</surname> <given-names>J</given-names></string-name>, <string-name name-style="western" hwp:sortable="Perry D"><surname>Perry</surname> <given-names>D</given-names></string-name>, <string-name name-style="western" hwp:sortable="Ramji J"><surname>Ramji</surname> <given-names>J</given-names></string-name>, <string-name name-style="western" hwp:sortable="Crawford K"><surname>Crawford</surname> <given-names>K</given-names></string-name>, <string-name name-style="western" hwp:sortable="Lindblad AJ"><surname>Lindblad</surname> <given-names>AJ</given-names></string-name>, <string-name name-style="western" hwp:sortable="Korownyk C"><surname>Korownyk</surname> <given-names>C</given-names></string-name>, <string-name name-style="western" hwp:sortable="Kolber MR."><surname>Kolber</surname> <given-names>MR.</given-names></string-name> <article-title hwp:id="article-title-3">Systematic review of systematic reviews for medical cannabinoids: Pain, nausea and vomiting, spasticity, and harms</article-title>. <source hwp:id="source-2">Can Fam Physician.</source> <year>2018</year> Feb;<volume>64</volume>(<issue>2</issue>):<fpage>e78</fpage>–<lpage>e94</lpage>.</citation></ref><ref id="c3" hwp:id="ref-3" hwp:rev-id="xref-ref-3-1 xref-ref-3-2 xref-ref-3-3 xref-ref-3-4"><label>3.</label><citation publication-type="journal" citation-type="journal" ref:id="389973v1.3" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-3"><string-name name-style="western" hwp:sortable="Wright S"><surname>Wright</surname> <given-names>S</given-names></string-name>, <string-name name-style="western" hwp:sortable="Ware M"><surname>Ware</surname> <given-names>M</given-names></string-name>, <string-name name-style="western" hwp:sortable="Guy G."><surname>Guy</surname> <given-names>G.</given-names></string-name> <article-title hwp:id="article-title-4">The use of a cannabis-based medicine (Sativex) in the treatment of pain caused by rheumatoid arthritis</article-title>. <source hwp:id="source-3">Rheumatology (Oxford)</source>. <year>2006</year> Jun;<volume>45</volume>(<issue>6</issue>):<fpage>781</fpage>; author reply 781-2. Epub 2006 Apr 18. PMID:<pub-id pub-id-type="pmid">16621924</pub-id></citation></ref><ref id="c4" hwp:id="ref-4" hwp:rev-id="xref-ref-4-1 xref-ref-4-2 xref-ref-4-3"><label>4.</label><citation publication-type="journal" citation-type="journal" ref:id="389973v1.4" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-4"><string-name name-style="western" hwp:sortable="Líndal E"><surname>Líndal</surname> <given-names>E</given-names></string-name>, <string-name name-style="western" hwp:sortable="Thorlacius S"><surname>Thorlacius</surname> <given-names>S</given-names></string-name>, <string-name name-style="western" hwp:sortable="Stefánsson JG"><surname>Stefánsson</surname> <given-names>JG</given-names></string-name>, <string-name name-style="western" hwp:sortable="Steinsson K."><surname>Steinsson</surname> <given-names>K.</given-names></string-name> <article-title hwp:id="article-title-5">Pain and pain problems among subjects with systemic lupus erythematosus in Iceland</article-title>. <source hwp:id="source-4">Scand J Rheumatol.</source> <year>1993</year>;<volume>22</volume>(<issue>1</issue>):<fpage>10</fpage>–<lpage>3</lpage>. PMID: <pub-id pub-id-type="pmid">8434240</pub-id></citation></ref><ref id="c5" hwp:id="ref-5" hwp:rev-id="xref-ref-5-1"><label>5.</label><citation publication-type="journal" citation-type="journal" ref:id="389973v1.5" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-5"><string-name name-style="western" hwp:sortable="Hochberg MC."><surname>Hochberg</surname> <given-names>MC.</given-names></string-name> <article-title hwp:id="article-title-6">Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus</article-title>. <source hwp:id="source-5">Arthritis Rheum</source> <year>1997</year> Sep;<volume>40</volume>(<issue>9</issue>):<fpage>1725</fpage>. PMID:<pub-id pub-id-type="pmid">9324032</pub-id></citation></ref><ref id="c6" hwp:id="ref-6" hwp:rev-id="xref-ref-6-1"><label>6.</label><citation publication-type="journal" citation-type="journal" ref:id="389973v1.6" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-6"><string-name name-style="western" hwp:sortable="Gladman DD"><surname>Gladman</surname> <given-names>DD</given-names></string-name>, <string-name name-style="western" hwp:sortable="Ibañez D"><surname>Ibañez</surname> <given-names>D</given-names></string-name>, <string-name name-style="western" hwp:sortable="Urowitz MB."><surname>Urowitz</surname> <given-names>MB.</given-names></string-name> <article-title hwp:id="article-title-7">Systemic lupus erythematosus disease activity index 2000</article-title>. <source hwp:id="source-6">J Rheumatol.</source> <year>2002</year> Feb;<volume>29</volume>(<issue>2</issue>):<fpage>288</fpage>–<lpage>91</lpage>.</citation></ref><ref id="c7" hwp:id="ref-7" hwp:rev-id="xref-ref-7-1"><label>7.</label><citation publication-type="journal" citation-type="journal" ref:id="389973v1.7" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-7"><string-name name-style="western" hwp:sortable="Gladman D"><surname>Gladman</surname> <given-names>D</given-names></string-name>, <string-name name-style="western" hwp:sortable="Ginzler E"><surname>Ginzler</surname> <given-names>E</given-names></string-name>, <string-name name-style="western" hwp:sortable="Goldsmith C"><surname>Goldsmith</surname> <given-names>C</given-names></string-name>, <string-name name-style="western" hwp:sortable="Fortin P"><surname>Fortin</surname> <given-names>P</given-names></string-name>, <string-name name-style="western" hwp:sortable="Liang M"><surname>Liang</surname> <given-names>M</given-names></string-name>, <string-name name-style="western" hwp:sortable="Urowitz M"><surname>Urowitz</surname> <given-names>M</given-names></string-name>, <etal>et al.</etal> <article-title hwp:id="article-title-8">The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus</article-title>. <source hwp:id="source-7">Arthritis Rheum.</source> <year>1996</year> Mar;<volume>39</volume>(<issue>3</issue>):<fpage>363</fpage>–<lpage>9</lpage>. PMID:<pub-id pub-id-type="pmid">8607884</pub-id></citation></ref><ref id="c8" hwp:id="ref-8" hwp:rev-id="xref-ref-8-1 xref-ref-8-2"><label>8.</label><citation publication-type="journal" citation-type="journal" ref:id="389973v1.8" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-8"><collab hwp:id="collab-1">American College of Rheumatology</collab>. <article-title hwp:id="article-title-9">The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes</article-title>. <source hwp:id="source-8">Arthritis Rheum</source>. <year>1999</year> Apr;<volume>42</volume>(<issue>4</issue>):<fpage>599</fpage>–<lpage>608</lpage>. PMID:<pub-id pub-id-type="pmid">10211873</pub-id></citation></ref><ref id="c9" hwp:id="ref-9" hwp:rev-id="xref-ref-9-1"><label>9.</label><citation publication-type="website" citation-type="web" ref:id="389973v1.9" ref:linkable="no" ref:use-reference-as-is="yes" hwp:id="citation-9"><collab hwp:id="collab-2">Centers for Disease Control and Preventiona</collab>. <source hwp:id="source-9">CDC Guideline for Prescribing Opioids for Chronic Pain</source>. <ext-link l:rel="related" l:ref-type="uri" l:ref="https://www.cdc.gov/drugoverdose/prescribing/guideline.html" ext-link-type="uri" xlink:href="https://www.cdc.gov/drugoverdose/prescribing/guideline.html" hwp:id="ext-link-2">https://www.cdc.gov/drugoverdose/prescribing/guideline.html</ext-link> accessed <date-in-citation content-type="access-date">09/29/2017</date-in-citation>.</citation></ref><ref id="c10" hwp:id="ref-10" hwp:rev-id="xref-ref-10-1"><label>10.</label><citation publication-type="other" citation-type="journal" ref:id="389973v1.10" ref:linkable="no" ref:use-reference-as-is="yes" hwp:id="citation-10"><collab hwp:id="collab-3">U.S., Social Security Death Index</collab>, <fpage>1935</fpage>–<lpage>2014</lpage>. <article-title hwp:id="article-title-10">Ancestry.com. Original data: Social Security Administration. Social Security Death Index, Master File</article-title>. <source hwp:id="source-10">Social Security Administration</source>, USA. <ext-link l:rel="related" l:ref-type="uri" l:ref="http://search.ancestry.com/search/db.aspx?dbid=3693" ext-link-type="uri" xlink:href="http://search.ancestry.com/search/db.aspx?dbid=3693" hwp:id="ext-link-3">http://search.ancestry.com/search/db.aspx?dbid=3693</ext-link>, accessed <date-in-citation content-type="access-date">Sept.25</date-in-citation>, <year>2017</year>.</citation></ref><ref id="c11" hwp:id="ref-11" hwp:rev-id="xref-ref-11-1"><label>11.</label><citation publication-type="journal" citation-type="journal" ref:id="389973v1.11" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-11"><string-name name-style="western" hwp:sortable="Di Franco M"><surname>Di Franco</surname> <given-names>M</given-names></string-name>, <string-name name-style="western" hwp:sortable="Guzzo MP"><surname>Guzzo</surname> <given-names>MP</given-names></string-name>, <string-name name-style="western" hwp:sortable="Spinelli FR"><surname>Spinelli</surname> <given-names>FR</given-names></string-name>, <string-name name-style="western" hwp:sortable="Atzeni F"><surname>Atzeni</surname> <given-names>F</given-names></string-name>, <string-name name-style="western" hwp:sortable="Sarzi-Puttini P"><surname>Sarzi-Puttini</surname> <given-names>P</given-names></string-name>, <string-name name-style="western" hwp:sortable="Conti F"><surname>Conti</surname> <given-names>F</given-names></string-name>, <string-name name-style="western" hwp:sortable="Iannuccelli C."><surname>Iannuccelli</surname> <given-names>C.</given-names></string-name> <article-title hwp:id="article-title-11">Pain and systemic lupus erythematosus</article-title>. <source hwp:id="source-11">Reumatismo</source> <year>2014</year> Jun 6;<volume>66</volume>(<issue>1</issue>):<fpage>33</fpage>–<lpage>8</lpage>. doi: <pub-id pub-id-type="doi">10.4081/reumatismo.2014.762</pub-id>. PMID:<pub-id pub-id-type="pmid">24938194</pub-id></citation></ref><ref id="c12" hwp:id="ref-12" hwp:rev-id="xref-ref-12-1"><label>12.</label><citation publication-type="journal" citation-type="journal" ref:id="389973v1.12" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-12"><string-name name-style="western" hwp:sortable="Fischin J"><surname>Fischin</surname> <given-names>J</given-names></string-name>, <string-name name-style="western" hwp:sortable="Chehab G"><surname>Chehab</surname> <given-names>G</given-names></string-name>, <string-name name-style="western" hwp:sortable="Richter JG"><surname>Richter</surname> <given-names>JG</given-names></string-name>, <string-name name-style="western" hwp:sortable="Fischer-Betz R"><surname>Fischer-Betz</surname> <given-names>R</given-names></string-name>, <string-name name-style="western" hwp:sortable="Winkler-Rohlfing B"><surname>Winkler-Rohlfing</surname> <given-names>B</given-names></string-name>, <string-name name-style="western" hwp:sortable="Willers R"><surname>Willers</surname> <given-names>R</given-names></string-name>, <string-name name-style="western" hwp:sortable="Schneider M."><surname>Schneider</surname> <given-names>M.</given-names></string-name> <article-title hwp:id="article-title-12">Factors associated with pain coping and catastrophising in patients with systemic lupus erythematosus: a cross-sectional study of the LuLa-cohort</article-title>. <source hwp:id="source-12">Lupus Sci Med.</source> <year>2015</year> Nov <volume>12;2</volume>(<issue>1</issue>):<fpage>e000113</fpage>. doi: <pub-id pub-id-type="doi">10.1136/lupus-2015-000113</pub-id>. eCollection 2015 PMID:<pub-id pub-id-type="pmid">26629351</pub-id></citation></ref><ref id="c13" hwp:id="ref-13" hwp:rev-id="xref-ref-13-1 xref-ref-13-2"><label>13.</label><citation publication-type="journal" citation-type="journal" ref:id="389973v1.13" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-13"><string-name name-style="western" hwp:sortable="Davstad I"><surname>Davstad</surname> <given-names>I</given-names></string-name>, <string-name name-style="western" hwp:sortable="Allebeck P"><surname>Allebeck</surname> <given-names>P</given-names></string-name>, <string-name name-style="western" hwp:sortable="Leifman A"><surname>Leifman</surname> <given-names>A</given-names></string-name>, <string-name name-style="western" hwp:sortable="Stenbacka M"><surname>Stenbacka</surname> <given-names>M</given-names></string-name>, <string-name name-style="western" hwp:sortable="Romelsjö A."><surname>Romelsjö</surname> <given-names>A.</given-names></string-name> <article-title hwp:id="article-title-13">Self-reported drug use and mortality among a nationwide sample of Swedish conscripts - A 35-year follow-up</article-title>. <source hwp:id="source-13">Drug Alcohol Depend.</source> <year>2011</year> Nov <volume>1;118</volume>(<issue>2-3</issue>):<fpage>383</fpage>–<lpage>90</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.drugalcdep.2011.04.025</pub-id>. Epub 2011 Jun 12. PMID:<pub-id pub-id-type="pmid">21664771</pub-id></citation></ref><ref id="c14" hwp:id="ref-14" hwp:rev-id="xref-ref-14-1 xref-ref-14-2"><label>14.</label><citation publication-type="journal" citation-type="journal" ref:id="389973v1.14" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-14"><string-name name-style="western" hwp:sortable="Tektonidou MG"><surname>Tektonidou</surname> <given-names>MG</given-names></string-name>, <string-name name-style="western" hwp:sortable="Lewandowski LB"><surname>Lewandowski</surname> <given-names>LB</given-names></string-name>, <string-name name-style="western" hwp:sortable="Hu J"><surname>Hu</surname> <given-names>J</given-names></string-name>, <string-name name-style="western" hwp:sortable="Dasgupta A"><surname>Dasgupta</surname> <given-names>A</given-names></string-name>, <string-name name-style="western" hwp:sortable="Ward MM."><surname>Ward</surname> <given-names>MM.</given-names></string-name> <article-title hwp:id="article-title-14">Survival in adults and children with systemic lupus erythematosus: a systematic review and Bayesian meta-analysis of studies from 1950 to 2016</article-title>. <source hwp:id="source-14">Ann Rheum Dis.</source> <year>2017</year> Aug <volume>9</volume>. pii: <pub-id pub-id-type="pii">annrheumdis-2017-211663</pub-id>. doi: <pub-id pub-id-type="doi">10.1136/annrheumdis-2017-211663</pub-id>. [Epub ahead of print] PMID: <pub-id pub-id-type="pmid">28794077</pub-id></citation></ref><ref id="c15" hwp:id="ref-15" hwp:rev-id="xref-ref-15-1 xref-ref-15-2 xref-ref-15-3 xref-ref-15-4"><label>15.</label><citation publication-type="journal" citation-type="journal" ref:id="389973v1.15" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-15"><string-name name-style="western" hwp:sortable="Gross IM"><surname>Gross</surname> <given-names>IM</given-names></string-name>, <string-name name-style="western" hwp:sortable="Hosek S"><surname>Hosek</surname> <given-names>S</given-names></string-name>, <string-name name-style="western" hwp:sortable="Richards MH"><surname>Richards</surname> <given-names>MH</given-names></string-name>, <string-name name-style="western" hwp:sortable="Fernandez MI."><surname>Fernandez</surname> <given-names>MI.</given-names></string-name> <article-title hwp:id="article-title-15">Predictors and Profiles of Antiretroviral Therapy Adherence Among African American Adolescents and Young Adult Males Living with HIV</article-title>. <source hwp:id="source-15">AIDS Patient Care STDS.</source> <year>2016</year> Jul;<volume>30</volume>(<issue>7</issue>):<fpage>324</fpage>–<lpage>38</lpage>.</citation></ref><ref id="c16" hwp:id="ref-16" hwp:rev-id="xref-ref-16-1"><label>16.</label><citation publication-type="journal" citation-type="journal" ref:id="389973v1.16" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-16"><string-name name-style="western" hwp:sortable="Isidro ML"><surname>Isidro</surname> <given-names>ML</given-names></string-name>, <string-name name-style="western" hwp:sortable="Jorge S."><surname>Jorge</surname> <given-names>S.</given-names></string-name> <article-title hwp:id="article-title-16">Recreational drug abuse in patients hospitalized for diabetic ketosis or diabetic ketoacidosis</article-title>. <source hwp:id="source-16">Acta Diabetol.</source> <year>2013</year> Apr;<volume>50</volume>(<issue>2</issue>):<fpage>183</fpage>–<lpage>7</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s00592-010-0243-z</pub-id>. Epub 2010 Dec 7. PMID:<pub-id pub-id-type="pmid">21136122</pub-id></citation></ref><ref id="c17" hwp:id="ref-17" hwp:rev-id="xref-ref-17-1 xref-ref-17-2 xref-ref-17-3 xref-ref-17-4"><label>17.</label><citation publication-type="journal" citation-type="journal" ref:id="389973v1.17" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-17"><string-name name-style="western" hwp:sortable="Stewart SL"><surname>Stewart</surname> <given-names>SL</given-names></string-name>, <string-name name-style="western" hwp:sortable="Baiden P."><surname>Baiden</surname> <given-names>P.</given-names></string-name> <article-title hwp:id="article-title-17">An exploratory study of the factors associated with medication nonadherence among youth in adult mental health facilities in Ontario, Canada</article-title>. <source hwp:id="source-17">Psychiatry Res.</source> <year>2013</year> May <volume>30;207</volume>(<issue>3</issue>):<fpage>212</fpage>–<lpage>7</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.psychres.2013.01.017</pub-id>. Epub 2013 Mar 5. PMID:<pub-id pub-id-type="pmid">23465295</pub-id></citation></ref><ref id="c18" hwp:id="ref-18" hwp:rev-id="xref-ref-18-1"><label>18.</label><citation publication-type="journal" citation-type="journal" ref:id="389973v1.18" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-18"><string-name name-style="western" hwp:sortable="Mehat P"><surname>Mehat</surname> <given-names>P</given-names></string-name>, <string-name name-style="western" hwp:sortable="Atiquzzaman M"><surname>Atiquzzaman</surname> <given-names>M</given-names></string-name>, <string-name name-style="western" hwp:sortable="Esdaile JM"><surname>Esdaile</surname> <given-names>JM</given-names></string-name>, <string-name name-style="western" hwp:sortable="AviÑa-Zubieta A"><surname>AviÑa-Zubieta</surname> <given-names>A</given-names></string-name>, <string-name name-style="western" hwp:sortable="De Vera MA."><surname>De Vera</surname> <given-names>MA.</given-names></string-name> <article-title hwp:id="article-title-18">Medication Nonadherence in Systemic Lupus Erythematosus: A Systematic Review</article-title>. <source hwp:id="source-18">Arthritis Care Res (Hoboken)</source>. <year>2017</year> Nov;<volume>69</volume>(<issue>11</issue>):<fpage>1706</fpage>–<lpage>1713</lpage>.</citation></ref><ref id="c19" hwp:id="ref-19" hwp:rev-id="xref-ref-19-1"><label>19.</label><citation publication-type="journal" citation-type="journal" ref:id="389973v1.19" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-19"><string-name name-style="western" hwp:sortable="Feldman CH"><surname>Feldman</surname> <given-names>CH</given-names></string-name>, <string-name name-style="western" hwp:sortable="Collins J"><surname>Collins</surname> <given-names>J</given-names></string-name>, <string-name name-style="western" hwp:sortable="Zhang Z"><surname>Zhang</surname> <given-names>Z</given-names></string-name>, <string-name name-style="western" hwp:sortable="Subramanian SV"><surname>Subramanian</surname> <given-names>SV</given-names></string-name>, <string-name name-style="western" hwp:sortable="Solomon DH"><surname>Solomon</surname> <given-names>DH</given-names></string-name>, <string-name name-style="western" hwp:sortable="Kawachi I"><surname>Kawachi</surname> <given-names>I</given-names></string-name>, <string-name name-style="western" hwp:sortable="Costenbader KH."><surname>Costenbader</surname> <given-names>KH.</given-names></string-name> <article-title hwp:id="article-title-19">Dynamic patterns and predictors of hydroxychloroquine nonadherence among Medicaid beneficiaries with systemic lupus erythematosus</article-title>. <source hwp:id="source-19">Semin Arthritis Rheum.</source> <year>2018</year> Jan <volume>8</volume>. pii: <pub-id pub-id-type="pii">S0049-0172(17)30376-1</pub-id>. doi: <pub-id pub-id-type="doi">10.1016/j.semarthrit.2018.01.002 [Epub ahead of print]</pub-id></citation></ref><ref id="c20" hwp:id="ref-20" hwp:rev-id="xref-ref-20-1"><label>20.</label><citation publication-type="journal" citation-type="journal" ref:id="389973v1.20" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-20"><string-name name-style="western" hwp:sortable="Feldman CH"><surname>Feldman</surname> <given-names>CH</given-names></string-name>, <string-name name-style="western" hwp:sortable="Yazdany J"><surname>Yazdany</surname> <given-names>J</given-names></string-name>, <string-name name-style="western" hwp:sortable="Guan H"><surname>Guan</surname> <given-names>H</given-names></string-name>, <string-name name-style="western" hwp:sortable="Solomon DH"><surname>Solomon</surname> <given-names>DH</given-names></string-name>, <string-name name-style="western" hwp:sortable="Costenbader KH."><surname>Costenbader</surname> <given-names>KH.</given-names></string-name> <article-title hwp:id="article-title-20">Medication Nonadherence Is Associated With Increased Subsequent Acute Care Utilization Among Medicaid Beneficiaries With Systemic Lupus Erythematosus</article-title>. <source hwp:id="source-20">Arthritis Care Res (Hoboken)</source>. <year>2015</year> Dec;<volume>67</volume>(<issue>12</issue>):<fpage>1712</fpage>–<lpage>21</lpage></citation></ref><ref id="c21" hwp:id="ref-21" hwp:rev-id="xref-ref-21-1"><label>21.</label><citation publication-type="journal" citation-type="journal" ref:id="389973v1.21" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-21"><string-name name-style="western" hwp:sortable="Uribe AG"><surname>Uribe</surname> <given-names>AG</given-names></string-name>, <string-name name-style="western" hwp:sortable="Ho KT"><surname>Ho</surname> <given-names>KT</given-names></string-name>, <string-name name-style="western" hwp:sortable="Agee B"><surname>Agee</surname> <given-names>B</given-names></string-name>, <string-name name-style="western" hwp:sortable="McGwin G Jr"><surname>McGwin</surname> <given-names>G</given-names> <suffix>Jr</suffix></string-name>, <string-name name-style="western" hwp:sortable="Fessler BJ"><surname>Fessler</surname> <given-names>BJ</given-names></string-name>, <string-name name-style="western" hwp:sortable="Bastian HM"><surname>Bastian</surname> <given-names>HM</given-names></string-name>, <string-name name-style="western" hwp:sortable="Reveille JD"><surname>Reveille</surname> <given-names>JD</given-names></string-name>, <string-name name-style="western" hwp:sortable="Alarcón GS."><surname>Alarcón</surname> <given-names>GS.</given-names></string-name> <article-title hwp:id="article-title-21">Relationship between adherence to study and clinic visits in systemic lupus erythematosuspatients: data from the LUMINA cohort</article-title>. <source hwp:id="source-21">Lupus</source>. <year>2004</year>;<volume>13</volume>(<issue>8</issue>):<fpage>561</fpage>–<lpage>8</lpage>.</citation></ref><ref id="c22" hwp:id="ref-22" hwp:rev-id="xref-ref-22-1"><label>22.</label><citation publication-type="journal" citation-type="journal" ref:id="389973v1.22" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-22"><string-name name-style="western" hwp:sortable="Rivera F"><surname>Rivera</surname> <given-names>F</given-names></string-name>, <string-name name-style="western" hwp:sortable="Anaya S."><surname>Anaya</surname> <given-names>S.</given-names></string-name> <article-title hwp:id="article-title-22">Lupus nephritis flare in young patients: relapse or nonadherence to treatment?</article-title> <source hwp:id="source-22">Int J Nephrol Renovasc Dis.</source> <year>2014</year> Mar 27;<volume>7</volume>:<fpage>117</fpage>–<lpage>21</lpage>.</citation></ref><ref id="c23" hwp:id="ref-23" hwp:rev-id="xref-ref-23-1"><label>23.</label><citation publication-type="journal" citation-type="journal" ref:id="389973v1.23" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-23"><string-name name-style="western" hwp:sortable="Nevins TE"><surname>Nevins</surname> <given-names>TE</given-names></string-name>, <string-name name-style="western" hwp:sortable="Nickerson PW"><surname>Nickerson</surname> <given-names>PW</given-names></string-name>, <string-name name-style="western" hwp:sortable="Dew MA."><surname>Dew</surname> <given-names>MA.</given-names></string-name> <article-title hwp:id="article-title-23">Understanding Medication Nonadherence after Kidney Transplant</article-title>. <source hwp:id="source-23">J Am Soc Nephrol.</source> <year>2017</year> Aug;<volume>28</volume>(<issue>8</issue>):<fpage>2290</fpage>–<lpage>2301</lpage>.</citation></ref><ref id="c24" hwp:id="ref-24" hwp:rev-id="xref-ref-24-1 xref-ref-24-2"><label>24.</label><citation publication-type="journal" citation-type="journal" ref:id="389973v1.24" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-24"><string-name name-style="western" hwp:sortable="Chand S"><surname>Chand</surname> <given-names>S</given-names></string-name>, <string-name name-style="western" hwp:sortable="Atkinson D"><surname>Atkinson</surname> <given-names>D</given-names></string-name>, <string-name name-style="western" hwp:sortable="Collins C"><surname>Collins</surname> <given-names>C</given-names></string-name>, <string-name name-style="western" hwp:sortable="Briggs D"><surname>Briggs</surname> <given-names>D</given-names></string-name>, <string-name name-style="western" hwp:sortable="Ball S"><surname>Ball</surname> <given-names>S</given-names></string-name>, <string-name name-style="western" hwp:sortable="Sharif A"><surname>Sharif</surname> <given-names>A</given-names></string-name>, <string-name name-style="western" hwp:sortable="Skordilis K"><surname>Skordilis</surname> <given-names>K</given-names></string-name>, <string-name name-style="western" hwp:sortable="Vydianath B"><surname>Vydianath</surname> <given-names>B</given-names></string-name>, <string-name name-style="western" hwp:sortable="Neil D"><surname>Neil</surname> <given-names>D</given-names></string-name>, <string-name name-style="western" hwp:sortable="Borrows R."><surname>Borrows</surname> <given-names>R.</given-names></string-name> <article-title hwp:id="article-title-24">The Spectrum of Renal Allograft Failure</article-title>. <source hwp:id="source-24">PLoS One.</source> <year>2016</year> Sep <volume>20;11</volume>(<issue>9</issue>):e0162278. doi: <pub-id pub-id-type="doi">10.1371/journal.pone.0162278</pub-id>. eCollection 2016.</citation></ref><ref id="c25" hwp:id="ref-25" hwp:rev-id="xref-ref-25-1 xref-ref-25-2 xref-ref-25-3"><label>25.</label><citation publication-type="journal" citation-type="journal" ref:id="389973v1.25" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-25"><string-name name-style="western" hwp:sortable="Markusse HM"><surname>Markusse</surname> <given-names>HM</given-names></string-name>, <string-name name-style="western" hwp:sortable="van den Bent MJ"><surname>van den Bent</surname> <given-names>MJ</given-names></string-name>, <string-name name-style="western" hwp:sortable="Vecht CJ."><surname>Vecht</surname> <given-names>CJ.</given-names></string-name> <article-title hwp:id="article-title-25">Immunology in medical practice. XIV</article-title>. <source hwp:id="source-25">Central nervous system complications in systemic autoimmune diseases Ned Tijdschr Geneeskd</source>. <year>1998</year> Mar <volume>7;142</volume>(<issue>10</issue>):<fpage>508</fpage>–<lpage>12</lpage>. PMID:<pub-id pub-id-type="pmid">9623096</pub-id></citation></ref><ref id="c26" hwp:id="ref-26" hwp:rev-id="xref-ref-26-1"><label>26.</label><citation publication-type="journal" citation-type="journal" ref:id="389973v1.26" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-26"><string-name name-style="western" hwp:sortable="Fleming MF"><surname>Fleming</surname> <given-names>MF</given-names></string-name>, <string-name name-style="western" hwp:sortable="Balousek SL"><surname>Balousek</surname> <given-names>SL</given-names></string-name>, <string-name name-style="western" hwp:sortable="Klessig CL"><surname>Klessig</surname> <given-names>CL</given-names></string-name>, <string-name name-style="western" hwp:sortable="Mundt MP"><surname>Mundt</surname> <given-names>MP</given-names></string-name>, <string-name name-style="western" hwp:sortable="Brown DD."><surname>Brown</surname> <given-names>DD.</given-names></string-name> <article-title hwp:id="article-title-26">Substance use disorders in a primary care sample receiving daily opioid therapy</article-title>. <source hwp:id="source-26">J Pain</source>. <year>2007</year> Jul;<volume>8</volume>(<issue>7</issue>):<fpage>573</fpage>–<lpage>82</lpage>. Epub 2007 May 11. PMID:<pub-id pub-id-type="pmid">17499555</pub-id></citation></ref><ref id="c27" hwp:id="ref-27" hwp:rev-id="xref-ref-27-1"><label>27.</label><citation publication-type="journal" citation-type="journal" ref:id="389973v1.27" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-27"><string-name name-style="western" hwp:sortable="Croca SC"><surname>Croca</surname> <given-names>SC</given-names></string-name>, <string-name name-style="western" hwp:sortable="Rodrigues T"><surname>Rodrigues</surname> <given-names>T</given-names></string-name>, <string-name name-style="western" hwp:sortable="Isenberg DA."><surname>Isenberg</surname> <given-names>DA.</given-names></string-name> <article-title hwp:id="article-title-27">Assessment of a lupus nephritis cohort over a 30-year period</article-title>. <source hwp:id="source-27">Rheumatology (Oxford)</source>. <year>2011</year> Aug;<volume>50</volume>(<issue>8</issue>):<fpage>1424</fpage>–<lpage>30</lpage>. doi: <pub-id pub-id-type="doi">10.1093/rheumatology/ker101</pub-id>. Epub 2011 Mar 16. PMID: <pub-id pub-id-type="pmid">21415024</pub-id></citation></ref><ref id="c28" hwp:id="ref-28" hwp:rev-id="xref-ref-28-1"><label>28.</label><citation publication-type="journal" citation-type="journal" ref:id="389973v1.28" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-28"><string-name name-style="western" hwp:sortable="Franco C"><surname>Franco</surname> <given-names>C</given-names></string-name>, <string-name name-style="western" hwp:sortable="Yoo W"><surname>Yoo</surname> <given-names>W</given-names></string-name>, <string-name name-style="western" hwp:sortable="Franco D"><surname>Franco</surname> <given-names>D</given-names></string-name>, <string-name name-style="western" hwp:sortable="Xu Z."><surname>Xu</surname> <given-names>Z.</given-names></string-name> <article-title hwp:id="article-title-28">Predictors of end stage renal disease in African Americans with lupus nephritis</article-title>. <source hwp:id="source-28">Bull NYU Hosp Jt Dis.</source> <year>2010</year>;<volume>68</volume>(<issue>4</issue>):<fpage>251</fpage>–<lpage>6</lpage>. PMID:<pub-id pub-id-type="pmid">21162701</pub-id></citation></ref><ref id="c29" hwp:id="ref-29" hwp:rev-id="xref-ref-29-1"><label>29.</label><citation publication-type="journal" citation-type="journal" ref:id="389973v1.29" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-29"><string-name name-style="western" hwp:sortable="Bohatyrewicz M"><surname>Bohatyrewicz</surname> <given-names>M</given-names></string-name>, <string-name name-style="western" hwp:sortable="Urasinska E"><surname>Urasinska</surname> <given-names>E</given-names></string-name>, <string-name name-style="western" hwp:sortable="Rozanski J"><surname>Rozanski</surname> <given-names>J</given-names></string-name>, <string-name name-style="western" hwp:sortable="Ciechanowski K."><surname>Ciechanowski</surname> <given-names>K.</given-names></string-name> <article-title hwp:id="article-title-29">Membranous glomerulonephritis may be associated with heavy marijuana abuse</article-title>. <source hwp:id="source-29">Transplant Proc.</source> <year>2007</year> Dec;<volume>39</volume>(<issue>10</issue>):<fpage>3054</fpage>–<lpage>6</lpage>. PMID:<pub-id pub-id-type="pmid">18089320</pub-id></citation></ref><ref id="c30" hwp:id="ref-30" hwp:rev-id="xref-ref-30-1"><label>30.</label><citation publication-type="journal" citation-type="journal" ref:id="389973v1.30" ref:linkable="yes" ref:use-reference-as-is="yes" hwp:id="citation-30"><string-name name-style="western" hwp:sortable="Greenan G"><surname>Greenan</surname> <given-names>G</given-names></string-name>, <string-name name-style="western" hwp:sortable="Ahmad SB"><surname>Ahmad</surname> <given-names>SB</given-names></string-name>, <string-name name-style="western" hwp:sortable="Anders MG"><surname>Anders</surname> <given-names>MG</given-names></string-name>, <string-name name-style="western" hwp:sortable="Leeser A"><surname>Leeser</surname> <given-names>A</given-names></string-name>, <string-name name-style="western" hwp:sortable="Bromberg JS"><surname>Bromberg</surname> <given-names>JS</given-names></string-name>, <string-name name-style="western" hwp:sortable="Niederhaus SV."><surname>Niederhaus</surname> <given-names>SV.</given-names></string-name> <article-title hwp:id="article-title-30">Recreational marijuana use is not associated with worse outcomes after renal transplantation</article-title>. <source hwp:id="source-30">Clin Transplant.</source> <year>2016</year> Oct;<volume>30</volume>(<issue>10</issue>):<fpage>1340</fpage>–<lpage>1346</lpage>.</citation></ref></ref-list></back></article>
